New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

Aptevo Therapeutics Inc. (NASDAQ:APVO) shares plunged about 18% on Tuesday even after the company reported promising interim clinical results for its acute myeloid leukemia (AML) treatment candidate, ...

Blackstone Inc. (NYSE:BX) is one of the best undervalued stocks to invest in right now. Barclays cut the price target on ...

The clinical-stage biotechnology company announced that mipletamig, combined with venetoclax and azacitidine, delivered an 86% clinical benefit rate in newly diagnosed acute myeloid leukemia patients ...

Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutic ...

Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo ...

Rigel Pharmaceuticals maintains strong sales momentum across its three approved targeted therapies. Learn why RIGL stock is a Buy.

Selected as a C-Further program with up to $1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial ...

Zemcelpro (R) (dorocubicel), also known as UM171 Cell Therapy, is a novel personalized cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded ...

My grandpa dead was a blessing shadowed by the pain he was forced to endure because our state laws refused to give him ...

Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.